| Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis |
CONSHOHOCKEN, Pa., May 10, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced positive two-year results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of Rezdiffra. Patients (n=122) in the study achieved significant improvements from baseline in liver stiffness, liver fat, fibrosis biomarkers, liver volume and risk scores for clinically significant portal hypertension (CSPH). |
globenewswire.com |
2025-05-10 11:15:00 |
Czytaj oryginał (ang.) |
| Madrigal Pharmaceuticals: An Encouraging Start For Rezdiffra |
Madrigal Pharmaceuticals has a first-mover advantage in the huge MASH market due to the approval of Rezdiffra just over a year ago. The initial rollout of the compound is encouraging, and the company is expecting a huge surge in revenues in FY2025. Most analyst firms are positive around the company's prospects, and Madrigal has some potential additional catalysts on the horizon. |
seekingalpha.com |
2025-05-06 20:20:00 |
Czytaj oryginał (ang.) |
| Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2025 Earnings Call Transcript |
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL ) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Tina Ventura - Chief Investor Relations Officer Bill Sibold - Chief Executive Officer and Director Mardi Dier - Chief Financial Officer Conference Call Participants Eliana Merle - UBS Andrea Newkirk - Goldman Sachs Ritu Baral - TD Cowen Akash Tewari - Jefferies Yasmeen Rahimi - Piper Sandler Liisa Bayko - Evercore Jay Olson - Oppenheimer Mayank Mamtani - B. Riley Securities Prakhar Agrawal - Cantor Fitzgerald Operator Good day, and thank you for standing by. |
seekingalpha.com |
2025-05-01 17:01:35 |
Czytaj oryginał (ang.) |
| Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up |
MDGL stock is rising as it reports better-than-expected first-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales. |
zacks.com |
2025-05-01 15:40:35 |
Czytaj oryginał (ang.) |
| Madrigal (MDGL) Reports Q1 Loss, Tops Revenue Estimates |
Madrigal (MDGL) came out with a quarterly loss of $3.32 per share versus the Zacks Consensus Estimate of a loss of $3.62. This compares to loss of $7.38 per share a year ago. |
zacks.com |
2025-05-01 13:20:36 |
Czytaj oryginał (ang.) |
| Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates |
CONSHOHOCKEN, Pa., May 01, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reports first-quarter 2025 financial results and provides corporate updates. |
globenewswire.com |
2025-05-01 11:00:00 |
Czytaj oryginał (ang.) |
| Madrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL Congress |
CONSHOHOCKEN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced six presentations at the upcoming European Association for the Study of the Liver (EASL) Congress, taking place from May 7-10, 2025, in Amsterdam, the Netherlands. |
globenewswire.com |
2025-04-29 12:00:00 |
Czytaj oryginał (ang.) |
| Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025 |
CONSHOHOCKEN, Pa., April 18, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), announced today that it will release its first-quarter 2025 financial results on Thursday, May 1, 2025, prior to the open of the U.S. financial markets. |
globenewswire.com |
2025-04-18 12:00:00 |
Czytaj oryginał (ang.) |
| Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D. |
Dr. Taub's pioneering research in academia and industry led to the first FDA-approved therapy for patients with MASH Dr. Taub's pioneering research in academia and industry led to the first FDA-approved therapy for patients with MASH |
globenewswire.com |
2025-04-16 11:00:00 |
Czytaj oryginał (ang.) |
| Madrigal (MDGL) Up 0.5% Since Last Earnings Report: Can It Continue? |
Madrigal (MDGL) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2025-03-28 14:35:44 |
Czytaj oryginał (ang.) |
| Madrigal Appoints Jacqualyn A. Fouse, Ph.D. |
Fred Craves, Ph.D. to retire from Madrigal's Board of Directors in July 2025 CONSHOHOCKEN, Pa. |
globenewswire.com |
2025-03-11 10:00:00 |
Czytaj oryginał (ang.) |
| Madrigal Pharmaceuticals: Rezdiffra First-Mover Advantage Gains Traction (Upgrade) |
Madrigal Pharmaceuticals, Inc.'s Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity, but GLP-1 competition from Novo and Lilly poses significant future challenges. Madrigal's Phase 3 trial aims to expand Rezdiffra's label to early cirrhosis by 2027, with EMA approval expected in mid-2025. GLP-1s like semaglutide and tirzepatide show promising MASH results, potentially disrupting Rezdiffra's market despite its first-mover advantage. |
seekingalpha.com |
2025-02-28 16:29:58 |
Czytaj oryginał (ang.) |
| Madrigal Q4 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up |
MDGL stock is rising as it reports better-than-expected fourth-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales. |
zacks.com |
2025-02-26 14:55:23 |
Czytaj oryginał (ang.) |
| Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis |
On Wednesday, Madrigal Pharmaceuticals, Inc. MDGL reported two-year results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of Rezdiffra (resmetirom). |
benzinga.com |
2025-02-26 14:28:02 |
Czytaj oryginał (ang.) |
| Madrigal Pharmaceuticals Q4 Earnings Review: Strong Quarter, Even Stronger Outlook |
Madrigal Pharmaceuticals, Inc.'s Rezdiffra, the first approved drug for MASH, showed strong sales growth, with Q4 net sales up 66% to $103.3m. Despite a net loss of $466m in 2024, Madrigal's cash position improved to $931m, and Rezdiffra's market potential remains significant with no current competitors. Positive study data and upcoming European approval could further boost Rezdiffra's market presence, making Madrigal a prime M&A target. |
seekingalpha.com |
2025-02-26 13:41:08 |
Czytaj oryginał (ang.) |
| Why Madrigal Pharmaceuticals Stock Is Soaring Today |
Shares of Madrigal Pharmaceuticals (MDGL 16.35%) were soaring 15.2% higher as of 11:05 a.m. ET on Wednesday. |
fool.com |
2025-02-26 13:27:00 |
Czytaj oryginał (ang.) |
| Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2024 Earnings Call Transcript |
Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2024 Earnings Call Transcript |
seekingalpha.com |
2025-02-26 13:05:30 |
Czytaj oryginał (ang.) |
| Madrigal (MDGL) Reports Q4 Loss, Tops Revenue Estimates |
Madrigal (MDGL) came out with a quarterly loss of $2.71 per share versus the Zacks Consensus Estimate of a loss of $4.12. This compares to loss of $5.68 per share a year ago. |
zacks.com |
2025-02-26 11:31:15 |
Czytaj oryginał (ang.) |
| Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis |
CONSHOHOCKEN, Pa., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reports fourth-quarter and year-end 2024 financial results and reviews business highlights. |
globenewswire.com |
2025-02-26 09:00:00 |
Czytaj oryginał (ang.) |
| Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis |
CONSHOHOCKEN, Pa., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reported positive two-year results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of Rezdiffra (resmetirom). Patients treated with Rezdiffra achieved marked reductions in liver stiffness, a surrogate for fibrosis, measured by vibration-controlled transient elastography (VCTE). |
globenewswire.com |
2025-02-26 08:30:00 |
Czytaj oryginał (ang.) |
| Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference |
CONSHOHOCKEN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the 45th Annual TD Cowen Health Care Conference on Tuesday, March 4, 2025 at 11:10 A.M. ET. |
globenewswire.com |
2025-02-21 10:00:00 |
Czytaj oryginał (ang.) |
| Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025 |
CONSHOHOCKEN, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its fourth-quarter and full-year 2024 financial results on Wednesday, Feb. 26, 2025, prior to the open of the U.S. financial markets. |
globenewswire.com |
2025-02-12 10:00:00 |
Czytaj oryginał (ang.) |
| MoneyShow's Best Investment Ideas For 2025: Part 7 |
MoneyShow presents top investment ideas for 2025 from their contributors. This year's edition presents a broad mix of theme-based stock picks, momentum-driven high-flyers and beaten-up stocks with turnaround potential, along with some speculative plays and ETFs. Part 7 includes Village Super Market, MARA Holdings, Hess Midstream, ASML Holding and Ares Capital, among others. |
seekingalpha.com |
2025-01-29 13:50:00 |
Czytaj oryginał (ang.) |
| Madrigal Pharmaceuticals Rezdiffra Vies For Blockbuster Status In MASH |
Madrigal Pharma's REZDIFFRA achieved $100-$103M in Q4 sales, marking 61% growth, with market penetration of only 4% relative to TAM, indicating blockbuster potential. Potential competition from GLP-1 drugs and other MASH therapies exists, but REZDIFFRA's combination use and first-mover advantage mitigate these risks. Analysts project $515M in 2025 sales, driven by Medicare coverage, low market penetration, and European launch, making MDGL stock a STRONG BUY. |
seekingalpha.com |
2025-01-19 11:30:00 |
Czytaj oryginał (ang.) |
| Why Madrigal Pharmaceuticals Stock Was Plummeting This Week |
An estimates-beating set of preliminary financial numbers and two bullish analyst updates weren't enough to lift Madrigal Pharmaceuticals (MDGL -0.59%) stock out of the doldrums over the past few trading days. Investor expectations are clearly very high, as the company's share price had withered by nearly 20% week to date as of Friday before market open, according to data compiled by S&P Global Market Intelligence. |
fool.com |
2025-01-17 10:28:37 |
Czytaj oryginał (ang.) |
| MDGL Stock Down 10% on Disappointing Preliminary Q4 Rezdiffra Sales |
Madrigal stock slides 10% as the preliminary Q4 Rezdiffra sales figures failed to impress investors. |
zacks.com |
2025-01-15 12:46:20 |
Czytaj oryginał (ang.) |
| Why Madrigal Pharmaceuticals Stock Is Sinking Today |
Shares of Madrigal Pharmaceuticals (MDGL -13.81%) were sinking 13.3% lower as of 11:11 a.m. ET on Monday. |
fool.com |
2025-01-13 13:20:25 |
Czytaj oryginał (ang.) |
| Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra |
CONSHOHOCKEN, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced an update on its business performance, including preliminary* fourth-quarter and year-end net sales, year-end cash and patients on Rezdiffra. |
globenewswire.com |
2025-01-13 08:45:00 |
Czytaj oryginał (ang.) |
| Fast Drug Launch For Madrigal Pharmaceuticals Brings Buyout Discussion |
Rezdiffra's strong launch has been confirmed by robust sales in the first two quarters, even though it may have only been used in 2% of its current target patient population. Competitors with MASH therapies like NVO, SGMT, ALT and Boehringer Ingelheim are making progress, although the possibility of combinations could limit any downside for MDGL. There is ongoing discussion about a potential buyout, adding another layer of interest for investors, and a potential EU launch in H2'25. |
seekingalpha.com |
2025-01-09 08:22:17 |
Czytaj oryginał (ang.) |
| Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
CONSHOHOCKEN, Pa., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 2:15 pm PT. The presentation will be webcast live and can be accessed here or by visiting Madrigal's Investor Relations Site, Events and Presentations. |
globenewswire.com |
2025-01-03 10:00:00 |
Czytaj oryginał (ang.) |
| 3 Reasons Why Buying Madrigal Pharmaceuticals Today Is a Wise Move |
When a company's shares shoot up 82% in 12 months, investors clearly think it's a good time to be a shareholder -- and that's exactly what's happened to the stock of Madrigal Pharmaceuticals (MDGL 5.53%). Earlier this year, the up-and-coming biotech received approval of a pioneering liver-disease treatment. |
fool.com |
2024-11-23 09:46:00 |
Czytaj oryginał (ang.) |
| Madrigal (MDGL) Just Flashed Golden Cross Signal: Do You Buy? |
Madrigal Pharmaceuticals, Inc. (MDGL) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, MDGL's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross. |
zacks.com |
2024-11-22 12:56:10 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Believe Madrigal (MDGL) Could Rally 26.44%: Here's is How to Trade |
The average of price targets set by Wall Street analysts indicates a potential upside of 26.4% in Madrigal (MDGL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2024-11-18 13:00:45 |
Czytaj oryginał (ang.) |
| Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance |
Madrigal, Corcept, Catalyst Larimar and Theravance have been highlighted in this Industry Outlook article. |
zacks.com |
2024-11-11 10:51:11 |
Czytaj oryginał (ang.) |
| 1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More |
There's a bright future ahead for this company. |
fool.com |
2024-11-10 11:30:00 |
Czytaj oryginał (ang.) |
| 5 Small Drug Stocks to Buy as Trump Gets Re-Elected |
Innovation is at its peak for the Zacks Medical-Drugs industry. MDGL, CORT, CPRX, LRMR and TBPH may prove to be good additions to one's portfolio. |
zacks.com |
2024-11-08 10:21:31 |
Czytaj oryginał (ang.) |
| Here's Why Madrigal (MDGL) is a Great Momentum Stock to Buy |
Does Madrigal (MDGL) have what it takes to be a top stock pick for momentum investors? Let's find out. |
zacks.com |
2024-11-07 15:00:41 |
Czytaj oryginał (ang.) |
| Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences |
CONSHOHOCKEN, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences: |
globenewswire.com |
2024-11-06 10:00:00 |
Czytaj oryginał (ang.) |
| Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European Expansion |
Madrigal Pharmaceuticals' Rezdiffra has favorable initial market adoption and FDA approval, positioning it as a foundational therapy for NASH with advanced fibrosis. Broad insurance coverage and allowance for non-invasive testing [NIT] enhance patient accessibility and Rezdiffra's adoption rate. Competition from Novo Nordisk's Semaglutide poses a market risk, but Rezdiffra's liver-specific mechanism offers a targeted advantage. |
seekingalpha.com |
2024-11-03 11:00:00 |
Czytaj oryginał (ang.) |
| Madrigal Q3 Earnings Beat, NASH Drug Sales Drive Top Line, Stock Up |
MDGL stock is up as the company reports better-than-expected third-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales. |
zacks.com |
2024-11-01 12:46:12 |
Czytaj oryginał (ang.) |
| Madrigal (MDGL) Reports Q3 Loss, Tops Revenue Estimates |
Madrigal (MDGL) came out with a quarterly loss of $4.92 per share versus the Zacks Consensus Estimate of a loss of $6.94. This compares to loss of $5.34 per share a year ago. |
zacks.com |
2024-10-31 11:20:21 |
Czytaj oryginał (ang.) |
| Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting® |
CONSHOHOCKEN, Pa., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH), today announced multiple resmetirom data presentations at the upcoming American Association for the Study of Liver Diseases (AASLD) Liver Meeting, taking place from November 15-19, 2024 in San Diego. |
globenewswire.com |
2024-10-30 10:00:00 |
Czytaj oryginał (ang.) |
| Madrigal Pharmaceuticals: Looking To Finally Establish A Position Around The Q3 Earnings |
Madrigal Pharmaceuticals' Rezdiffra, approved for NASH, shows strong early demand and revenue growth, making Q3 earnings a potential catalyst for stock movement. Despite steep Q2 losses, Madrigal's $1.1B cash reserves and strategic execution position Rezdiffra as the market leader in NASH/MASH. Analysts forecast substantial revenue growth and narrowing losses for Madrigal, with expectations of profitability within a few years. |
seekingalpha.com |
2024-10-28 05:42:58 |
Czytaj oryginał (ang.) |
| Madrigal: Why I'm Having Doubts On The Bull Case Ahead Of Q3 Earnings |
Madrigal's Rezdiffra, the first FDA-approved drug for MASH, shows promise but faces competition from GLP-1 drugs and financial challenges in launching in Europe. Despite meeting Phase 3 endpoints and early sales success, Madrigal's Q3 earnings will be crucial in determining Rezdiffra's commercial viability and stock performance. The potential for Rezdiffra to achieve blockbuster status is tempered by its high cost and the emerging threat of GLP-1 agonists in the MASH market. |
seekingalpha.com |
2024-10-24 16:11:33 |
Czytaj oryginał (ang.) |
| Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis |
CONSHOHOCKEN, Pa., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH), today announced the MAESTRO-NASH OUTCOMES trial evaluating resmetirom for the treatment of patients with compensated NASH cirrhosis has completed enrollment. |
globenewswire.com |
2024-10-21 12:00:00 |
Czytaj oryginał (ang.) |
| Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024 |
CONSHOHOCKEN, Pa., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its third-quarter 2024 financial results on Thursday, Oct. 31, 2024, prior to the open of the U.S. financial markets. |
globenewswire.com |
2024-10-18 12:00:00 |
Czytaj oryginał (ang.) |
| Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference |
CONSHOHOCKEN, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced the company will participate in a fireside chat at the H.C. Wainwright 8th Annual MASH Virtual Investor Conference at 2:00 P.M. ET on Monday, Oct. 7, 2024. |
globenewswire.com |
2024-10-02 12:00:00 |
Czytaj oryginał (ang.) |
| Why Is Madrigal (MDGL) Up 1% Since Last Earnings Report? |
Madrigal (MDGL) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-09-06 16:37:52 |
Czytaj oryginał (ang.) |
| Is Madrigal Pharmaceuticals Stock a Buy? |
Madrigal Pharmaceuticals earned the first approval for a medicine in an area with a high unmet need. The biotech has more to do to dominate this market, considering it should become more crowded soon. |
fool.com |
2024-08-17 14:15:00 |
Czytaj oryginał (ang.) |